Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect

Iovance Biotherapeutics (IOVA) is scheduled to report first-quarter 2024 results on May 9, after market close. In the last reported quarter, the company’s earnings missed expectations by 2.27%.Factors to ConsiderThe Zacks Consensus Estimate for Iovance’s total revenues is pegged at around $2.9 million, while the same for earnings stands at a loss of 45 cents per share. Both metrics indicate improvements over the year-ago quarter’s levels.Iovance has two marketed products in its portfolio — Amtagvi (lifileuc ...